Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252111357 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jason F Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Metformin, Choroidal Neovascularization, Retinal Degeneration, Mice, Inbred C57BL. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, BrightFocus Foundation, Thome Memorial Foundation Award.
Abstract (Originalsprache)
Neovascular age-related macular degeneration (nAMD), a leading cause of blindness in older adults, presents a challenging pathophysiology involving choroidal neovascularization (CNV) and retinal degeneration. Current treatments relying on intravitreal (IVT) administration of anti-angiogenic agents are costly and of moderate effectiveness. Metformin, the common anti-diabetic drug, has been associated with decreased odds of developing AMD. Studies have shown that metformin can mitigate cellular aging, neoangiogenesis, and inflammation across multiple diseases. This preclinical study assessed metformin’s impact on vessel growth using choroidal explants before exploring IVT metformin’s effects on laser-induced CNV and light-induced retinal degeneration in C57BL/6J and BALB/cJ mice, respectively. Metformin reduced new vessel growth in choroidal explants in a dose-dependent relationship. Following laser induction, IVT metformin suppressed CNV and decreased peripheral infiltration of IBA1+ macrophages/microglia. Furthermore, IVT metformin protected against retinal thinning in response to light-induced degeneration. IVT metformin downregulated genes in the choroid and retinal pigment epithelium which are associated with angiogenesis and inflammation, two key processes that drive nAMD progression. These findings underscore metformin’s capacity as an anti-angiogenic and neuroprotective agent, demonstrating this drug’s potential as an accessible option to help manage nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL 60637, USA.
- Animal Resources Center, University of Chicago, Chicago, IL 60637, USA.
- Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
ORCID-Profile: Amir Mani, Aniruddhsingh Solanki, Jeremy A Lavine
Förderung
- NEI NIH HHS
- BrightFocus Foundation
- Thome Memorial Foundation Award
- Institute for Translational Medicine
- NIH HHS
- The University of Chicago Women's Board
- Illinois Society for the Prevention of Blindness
- FORE-I Foundation
Zitieren
APA
Xiao, J. F., Luo, W., Mani, A., Barba, H., Solanki, A., Droho, S., Lavine, J. A., & Skondra, D. (2024). Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111357
Vancouver
Xiao JF, Luo W, Mani A, Barba H, Solanki A, Droho S, et al. Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111357
BibTeX
@article{Xiao2024,
author = {Xiao, Jason F and Luo, Wendy and Mani, Amir and Barba, Hugo and Solanki, Aniruddhsingh and Droho, Steven and Lavine, Jeremy A and Skondra, Dimitra},
title = {Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252111357}
}
EUVIMED